Novartis CEO Holds 5% To 6% Growth Target After Two Late-Stage Trial Failures

Vas Narasimhan says the modeling is done, even after a $1.9 billion partial write-down of a neuromuscular drug.

Share
Novartis CEO Holds 5% To 6% Growth Target After Two Late-Stage Trial Failures

Novartis CEO Vas Narasimhan told analysts on the drugmaker's third-quarter earnings call Tuesday that two late-stage trial failures leave its 5% to 6% constant-currency sales growth target for 2025 to 2030 intact. "We've done all the modeling. We feel very comfortable with those numbers," he said.

Two misses, one write-down

The failures were del-desiran, which did not meet its main goal in the Phase 3 HARBOR study, and pelacarsen, whose Phase 3 HORIZON study missed its primary endpoint. Novartis, the Swiss medicines company behind Entresto, Cosentyx, Kisqali and Kesimpta, took a $1.9 billion partial impairment on del-desiran, which CFO Mukul Mehta said fed into a 61% decline in reported operating income to $1.8 billion.

Asked whether the charge meant changed assumptions, Narasimhan said Novartis assumes a similar probability of success and still expects to need another Phase 3 study. The charge was driven mainly by timelines shifting out, he said, adding: "I wouldn't read too much into these numbers."

Del-desiran came through the company's $12 billion purchase of Avidity Biosciences. Novartis disclosed in September that it failed against placebo, and the stock fell more than 10% that day.

What happens to pelacarsen

Narasimhan said the full HORIZON data will go to the American Heart Association meeting and a major journal. Novartis is weighing whether a patient group, such as people who have had an acute coronary event, justifies a new trial. Further development of its once-annual siRNA for Lp(a) is still under consideration.

He said the company will update midterm guidance for 2026 to 2031, along with peak sales estimates, at its Meet Novartis Management event in a few weeks.

Quarter beat the pipeline gloom

Third-quarter net sales rose 4% to $14.5 billion in constant currencies, and core operating income grew 10% to $6 billion, Mehta said. Core margin hit 41.6%. Novartis raised its 2026 core operating income outlook to flat to low-single-digit growth, from a low-single-digit decline, and kept its net sales outlook at low-single-digit growth.

Mehta said the company has bought back $2.8 billion of shares in the first nine months under its up-to-$10 billion program, with $4.9 billion left. It remains committed to finishing by the end of 2027, he said.

Novartis's market value stood at $292.3 billion in Tuesday trading, and the updated 2026-to-2031 targets are due at Meet Novartis Management in a few weeks.

Sources

More on Novartis

All Novartis (NVS) coverage →